Stock R G, Stone N N, DeWyngaert J K, Lavagnini P, Unger P D
Dpartment of Radiation Oncology, Mount Sinai School of Medicine, New York, New York 10029, USA.
Cancer. 1996 Jun 1;77(11):2386-92. doi: 10.1002/(SICI)1097-0142(19960601)77:11<2386::AID-CNCR30>3.0.CO;2-R.
Interactive, transrectal, ultrasound-guided transperineal implantation is a new technique for performing permanent brachytherapy implants of the prostate. Prostate specific antigen (PSA) findings, biopsy results, and morbidity are examined to demonstrate its efficacy and safety in treating early stage prostate carcinoma.
Ninety-seven patients underwent permanent implants for classifications T1 to T2 adenocarcinoma of the prostate gland with a median follow-up of 18 months (range: 6-51 months). Seventy-nine patients had negative laparoscopic pelvic lymph node dissections prior to implantation. Patients with positive lymph nodes were not implanted. The radioactive isotope used was I-125 in 71 patients and Pd-103 in 26 patients.
PSA failure was defined as two consecutive increases in PSA above the nadir level. The actuarial freedom from PSA failure (FFPF) at 2 years was 76% for the entire group. Stage significantly affected FFPF. Patients classified as T1b to T2a (35) had a FFPF of 91% at 2 years compared with 68.5% for patients classified as T2b to T2c (62) (P = 0.04). The pre-treatment PSA also significantly affected FFPF. Patients with PSA values of < or = 10 ng/mL (44) had a FFPF of 83% at 2 years. A similar rate of 82% was found in patients with PSA values of 10.1 to 20 ng/mL (29). Patients with PSA values > 20 ng/mL (24) had a significantly poorer FFPF at 2 years of 58% (P = 0.02). The PSA values of patients free from a PSA failure (82) ranged from 0.1 to 12.9 ng/mL with a median of 0.8 ng/mL. Transrectal prostate biopsies were performed 18 to 36 months posttreatment in 39 patients. Negative biopsies were found in 74% (29/39) of cases. The procedure was associated with an actuarial preservation of erectile function rate and sexual potency at 2 years of 96% and 79%, respectively. There were no cases of urinary incontinence or radiation cystitis. Associated morbidity included urinary retention requiring catheterization in 4% of the patients, outlet obstruction requiring a transurethral resection of the prostate in 2% and Grade 2 rectal complications in 1%.
Interactive, ultrasound-guided transperineal brachytherapy results in a low PSA failure rate, high negative biopsy rate, and is associated with low morbidity and preservation of erectile function.
交互式经直肠超声引导下经会阴植入是一种用于前列腺永久性近距离放射治疗植入的新技术。通过检测前列腺特异性抗原(PSA)结果、活检结果及发病率,以证明其在治疗早期前列腺癌中的疗效和安全性。
97例患者接受了前列腺T1至T2期腺癌的永久性植入,中位随访时间为18个月(范围:6 - 51个月)。79例患者在植入前进行了腹腔镜盆腔淋巴结清扫且结果为阴性。淋巴结阳性的患者未进行植入。71例患者使用的放射性同位素为碘 - 125,26例患者使用的是钯 - 103。
PSA失败定义为PSA连续两次升高超过最低点水平。整个组2年时的无PSA失败精算生存率(FFPF)为76%。分期显著影响FFPF。分类为T1b至T2a的患者(35例)2年时的FFPF为91%,而分类为T2b至T2c的患者(62例)为68.5%(P = 0.04)。治疗前的PSA也显著影响FFPF。PSA值≤10 ng/mL的患者(44例)2年时的FFPF为83%。PSA值在10.1至20 ng/mL的患者(29例)中发现类似的82%的比例。PSA值>20 ng/mL的患者(24例)2年时的FFPF明显较差,为58%(P = 0.02)。无PSA失败的患者(82例)的PSA值范围为0.1至12.9 ng/mL,中位数为0.8 ng/mL。39例患者在治疗后18至36个月进行了经直肠前列腺活检。74%(29/39)的病例活检结果为阴性。该手术2年时勃起功能保留率和性功能精算生存率分别为96%和79%。没有尿失禁或放射性膀胱炎的病例。相关并发症包括4%的患者需要导尿的尿潴留,2%的患者需要经尿道前列腺切除术的出口梗阻,以及1%的2级直肠并发症。
交互式超声引导下经会阴近距离放射治疗导致低PSA失败率、高阴性活检率,且与低发病率和勃起功能保留相关。